blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2254582

EP2254582 - METHODS OF TREATING VIRAL INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.11.2016
Database last updated on 03.10.2024
Most recent event   Tooltip13.07.2018Lapse of the patent in a contracting state
Updated state(s): MT		published on 15.08.2018  [2018/33]
Applicant(s)For all designated states
Chimerix, Inc.
2505 Meridian Parkway, Suite 340
Durham, NC 27713 / US
[2016/03]
Former [2010/48]For all designated states
Chimerix, Inc.
2505 Meridian Parkway, Suite 340
Durham, NC 27713 / US
Inventor(s)01 / LANIER, Ernest Randall
316 Reade Road
Chapel Hill North Carolina 27516 / US
02 / ALMOND, Merrick R.
1034 W. Sterlington Place
Apex North Carolina 27502 / US
03 / PAINTER, George R.
129 Red Bud Lane
Chapel Hill North Carolina 27514 / US
 [2010/48]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[N/P]
Former [2016/03]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Former [2013/15]Mintz Levin Cohn Ferris Glovsky and Popeo LLP
Alder Castle
10 Noble Street
London EC2V 7JX / GB
Former [2011/22]Ireland, Jacqueline Frances
Mintz Levin Cohn Ferris Glovsky and Popeo Intellectual Property LLP Alder Castle 10 Noble Street
London EC2V 7JX / GB
Former [2010/48]McNab, Donald C.
Marks & Clerk LLP Aurora 120 Bothwell Street Glasgow
G2 7JS / GB
Application number, filing date09704809.423.01.2009
[2010/48]
WO2009US00447
Priority number, dateUS2008002363325.01.2008         Original published format: US 23633
US2008010181001.10.2008         Original published format: US 101810
[2010/48]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009094190
Date:30.07.2009
Language:EN
[2009/31]
Type: A2 Application without search report 
No.:EP2254582
Date:01.12.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 30.07.2009 takes the place of the publication of the European patent application.
[2010/48]
Type: B1 Patent specification 
No.:EP2254582
Date:20.01.2016
Language:EN
[2016/03]
Search report(s)International search report - published on:KR01.10.2009
(Supplementary) European search report - dispatched on:EP17.06.2011
ClassificationIPC:A61K31/675, A61P31/18, A61P1/16, A61K9/20, A61K9/48, A61K9/14, C07H19/00, A61K31/14
[2010/48]
CPC:
A61K31/675 (EP,US); A61P1/16 (EP); A61P31/12 (EP);
A61P31/14 (EP); A61P31/18 (EP); A61P31/20 (EP);
A61P43/00 (EP); A61K2300/00 (US); A61K31/706 (EP,US);
A61K9/0014 (EP,US); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/03]
Former [2010/48]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON VIRUSINFEKTIONEN[2010/48]
English:METHODS OF TREATING VIRAL INFECTIONS[2010/48]
French:MÉTHODES DE TRAITEMENT D'INFECTIONS VIRALES[2010/48]
Entry into regional phase24.08.2010National basic fee paid 
24.08.2010Search fee paid 
24.08.2010Designation fee(s) paid 
24.08.2010Examination fee paid 
Examination procedure24.08.2010Examination requested  [2010/48]
05.01.2012Amendment by applicant (claims and/or description)
25.07.2013Despatch of a communication from the examining division (Time limit: M06)
31.01.2014Reply to a communication from the examining division
14.11.2014Despatch of a communication from the examining division (Time limit: M02)
22.01.2015Reply to a communication from the examining division
11.08.2015Communication of intention to grant the patent
09.12.2015Fee for grant paid
09.12.2015Fee for publishing/printing paid
09.12.2015Receipt of the translation of the claim(s)
Divisional application(s)EP16151475.7  / EP3085377
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.07.2013
Opposition(s)21.10.2016No opposition filed within time limit [2016/52]
Fees paidRenewal fee
25.01.2011Renewal fee patent year 03
25.01.2012Renewal fee patent year 04
25.01.2013Renewal fee patent year 05
27.01.2014Renewal fee patent year 06
26.01.2015Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.01.2009
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
TR20.01.2016
IE23.01.2016
LU23.01.2016
CH31.01.2016
LI31.01.2016
MT31.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
[2018/31]
Former [2018/30]HU23.01.2009
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
MT20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
TR20.01.2016
IE23.01.2016
LU23.01.2016
CH31.01.2016
LI31.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2018/28]HU23.01.2009
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
MT20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
IE23.01.2016
CH31.01.2016
LI31.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/47]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MT20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
IE23.01.2016
CH31.01.2016
LI31.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/15]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
IE23.01.2016
CH31.01.2016
LI31.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/07]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
IE23.01.2016
CH31.01.2016
LI31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/03]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
CH31.01.2016
LI31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/50]AT20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
BE31.01.2016
CH31.01.2016
LI31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/49]AT20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
NL20.01.2016
PL20.01.2016
SE20.01.2016
BE31.01.2016
CH31.01.2016
LI31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/46]AT20.01.2016
DK20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
SE20.01.2016
BE31.01.2016
CH31.01.2016
LI31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/39]AT20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
SE20.01.2016
BE31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/38]AT20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
NL20.01.2016
PL20.01.2016
BE31.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/36]AT20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
NL20.01.2016
PL20.01.2016
BE31.01.2016
NO20.04.2016
GR21.04.2016
Former [2016/35]FI20.01.2016
HR20.01.2016
NL20.01.2016
BE31.01.2016
NO20.04.2016
GR21.04.2016
Former [2016/30]NL20.01.2016
BE31.01.2016
Former [2016/24]BE31.01.2016
Documents cited:Search[XY]US2004019232  (HOSTETLER KARL Y [US], et al) [X] 1,3,4,9 * example 19; tables 5 and 6; §0135 * [Y] 1-15;
 [A]WO2006017044  (GILEAD SCIENCES INC [US], et al) [A] 10-15 * claims 8-12; §0010; §0030 *;
 [X]WO2006076015  (UNIV CALIFORNIA [US], et al) [X] 1,3,4,7-9 * comp. claims 14, 15 and p. 13, last §; table 2 *;
 [XY]CN1810816  (INST OF MEDICINE BIOTECHNOLOGY [CN]) [X] 1,3,4,9 * p.8, table I; compounds of formulae I and II; last § of p. 8 * [Y] 1-15;
 [X]WO2006110655  (CHIMERIX INC [US], et al) [X] 7,8 * claim 8; p. 3, l. 15; p. 10, l. 2 and p. 12, l. 4 *;
 [XY]  - PAINTER G R ET AL, "Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-ade nine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, (20071001), vol. 51, no. 10, doi:10.1128/AAC.00460-07, ISSN 0066-4804, pages 3505 - 3509, XP002485783 [X] 1,3,4,9 * abstract; first § of results; p. 3508, col.2, last § * [Y] 1-15

DOI:   http://dx.doi.org/10.1128/AAC.00460-07
 [Y]  - CIHLAR T ET AL, "Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 200802 US LNKD- DOI:10.1128/AAC.01215-07, (200712), vol. 52, no. 2, ISSN 0066-4804, pages 655 - 665, XP002637076 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1128/AAC.01215-07
 [Y]  - MYRICK ET AL, "The Triple Combination of Tenofovir, Emtricitabine and Efavirenz Shows Synergistic Anti-HIV-1 Activity In Vitro", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, (20070327), vol. 74, no. 3, doi:10.1016/J.ANTIVIRAL.2007.01.091, ISSN 0166-3542, page A61, XP022002118 [Y] 1-15 * whole document *

DOI:   http://dx.doi.org/10.1016/j.antiviral.2007.01.091
 [Y]  - RAY A S ET AL, "Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine", ANTIVIRAL THERAPY, MTM PUBLICATIONS, LONDON, GB, (20050101), vol. 10, no. 3, ISSN 1359-6535, pages 451 - 457, XP009148298 [Y] 1-15 * abstract *
 [Y]  - BORROTO-ESODA K ET AL, "In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine", ANTIVIRAL THERAPY, MTM PUBLICATIONS, LONDON, GB, (20060101), vol. 11, no. 3, ISSN 1359-6535, pages 377 - 384, XP009148299 [Y] 1-15 * abstract; tables 2-4 *
 [Y]  - LYSENG-WILLIAMSON K A ET AL, "Tenofovir disoproxil fumarate: A review of its use in the management of HIV infection", DRUGS, ADIS INTERNATIONAL LTD, NZ, (20050101), vol. 65, no. 3, doi:10.2165/00003495-200565030-00006, ISSN 0012-6667, pages 413 - 432, XP009148294 [Y] 1-15 * table IV; p. 416, col. 2, first full § *

DOI:   http://dx.doi.org/10.2165/00003495-200565030-00006
 [Y]  - DELANEY WILLIAM E 4TH ET AL, "COMBINATIONS OF ADEFOVIR WITH NUCLEOSIDE ANALOGS PRODUCE ADDITIVE ANTIVIRAL EFFECTS AGAINST HEPATITIS B VIRUS IN VITRO", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, (20041001), vol. 48, no. 10, doi:10.1128/AAC.48.10.3702-3710.2004, ISSN 0066-4804, pages 3702 - 3710, XP009077977 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1128/AAC.48.10.3702-3710.2004
 [Y]  - FUNG H B ET AL, "Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, (20021001), vol. 24, no. 10, doi:10.1016/S0149-2918(02)80058-3, ISSN 0149-2918, pages 1515 - 1548, XP002285091 [Y] 1-15 * p. 1523, col. 1, first § *

DOI:   http://dx.doi.org/10.1016/S0149-2918(02)80058-3
 [Y]  - FRANCHETTI P ET AL, "Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of lamivudine and tenofovir", NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, (2007), vol. 26, no. 8-9, ISSN 1525-7770, pages 953 - 957, XP009148476 [Y] 1-15 * abstract; title *

DOI:   http://dx.doi.org/10.1080/15257770701508067
International search[X]WO2005087788  (UNIV CALIFORNIA [US], et al);
 [Y]US2005267217  (BARON SAMUEL [US], et al);
 [Y]WO2006130217  (UNIV CALIFORNIA [US], et al)
ExaminationWO2009082818
by applicantUS5519021
 WO9962513
 WO9962520
 WO0039086
 WO0075122
 WO0100578
 US6245806
 US6271402
 WO0230426
 WO0230930
 WO0230931
 WO0236734
 US6395743
 WO02055079
 US2003055071
 US6545007
 US6583149
 US6642245
 US6716825
 WO2004035577
 WO2004035576
 WO2004096807
 WO2005016927
 WO2005079812
 US7034014
 US7094413
 US2006234982
 US2007003516
 US2007072831
 US2007099902
 US7250421
 US2007265227
 WO2008010921
    - PALELLA, N. ENGL. J. MED., (1998), vol. 338, pages 853 - 860
    - RICHMAN, NATURE, (2001), vol. 410, pages 995 - 1001
    - G. PAINTER ET AL., "Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2007), vol. 51, pages 3505 - 3509
    - PAINTER ET AL., "Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2007), vol. 51, pages 3505 - 3509
    - JING ET AL., BIOCHEMISTRY, (2002), vol. 41, pages 5397 - 5403
    - PAIS, J. MED. CHEM., (2002), vol. 45, pages 3184 - 94
    - GOLDGUR ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1999), vol. 96, pages 13040 - 13043
    - ESPESETH ET AL., PROC. NATL. ACAD. SCI. U.S.A., (2000), vol. 97, pages 11244 - 11249
    - M. MILLER ET AL., J INFECT DIS., (2004), vol. 189, page 837
    - LOUIE ET AL., "Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-l-infected individuals", AIDS, (2003), vol. 17, page 1151
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.